Search
Ubidecarenone
go.drugbank.com/drugs/DB09270ApprovedInvestigationalNutraceutical[L1062] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease.
Thimerosal
go.drugbank.com/drugs/DB11590ApprovedThiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. … Developed in 1927, thimerosal has been and is still being used as a preservative in some cosmetics, topical pharmaceuticals, and biological drug products, which includes vaccines.
Avacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigational[A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD.
Von Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigational[L40049] As vWF is normally present in the blood as a stable complex with coagulation factor III, therapeutic vWF products are also available as a combination product with [antihemophilic factor human]
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalIt was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co.
Products: PRAVASTATINA MYLAN GENERICS, PRAVASTATINA DOC GENERICIQuinidine
go.drugbank.com/drugs/DB00908ApprovedThis alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A7906] The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. … Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA).
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.